Episode 20. Management of Myeloma in LMICs
Blood Cancer Talks
The Importance of Early Relapse
In the private setting, we are leaning towards monoclonal antibodies as a first option after relapse. And that would be just minority of patients can actually access carfilzomide, an anti-CD38 antibodies. So this is a very difficult issue. Patients with myeloma here have a poor survival because they don't have access to these expensive therapies. We're probably going to see worse difference because over here, it's like 1999, right? We still have time does not pass.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
